ExpreS2ion Biotech
ExpreS2ion announces publication of sponsored research reports
The reports, authored by Analysguiden and Pareto Securities, provide detailed analyses of ExpreS2ion's lead asset, ES2B-C001, and the broader development pipeline.
Key Highlights:
- Analysguiden Report: Titled "At the Gates of Phase I," this report emphasizes the outlook for ES2B-C001 as it approaches Phase I clinical trials. Read the full report.
- Pareto Securities Report: This report provides a brief review of ExpreS2ion's Q2 2024 financial results. Read the full report.
Both reports highlight the transformative potential of the ExpreS2 platform for development of novel and improved vaccines and therapeutics for infectious diseases and cancer.
For more detailed insights and additional research reports, please visit the Analyst Reports page of our investor website.
Certified Adviser
Svensk Kapitalmarknadsgranskning AB
| Datum | 2024-08-23, kl 12:45 |
| Källa | Cision |
Kom igång med ditt sparande på bara några minuter! Hos Avanza handlar du aktier från 0 kr på Stockholmsbörsen och får tillbaka alla fondavgifter (ja, alla!) upp till 50 000 kr i samlat sparande. Kanske är det därför Avanza har Sveriges nöjdaste sparare 15 år i rad.
Investeringar innebär en risk